Business Description
Samrat Pharmachem Ltd
ISIN : INE103E01016
Share Class Description:
BOM:530125: Shs DematerialisedCompare
Compare
Traded in other countries / regions
530125.India IPO Date
2001-10-17Description
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.15 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | 1.47 | |||||
| Interest Coverage | 7.03 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 5.38 | |||||
| Beneish M-Score | -1.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.3 | |||||
| 3-Year EBITDA Growth Rate | -24.9 | |||||
| 3-Year EPS without NRI Growth Rate | -38.2 | |||||
| 3-Year FCF Growth Rate | 61.7 | |||||
| 3-Year Book Growth Rate | 29.9 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.58 | |||||
| 9-Day RSI | 43.37 | |||||
| 14-Day RSI | 43.98 | |||||
| 6-1 Month Momentum % | 45.69 | |||||
| 12-1 Month Momentum % | 38.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.82 | |||||
| Quick Ratio | 1.45 | |||||
| Cash Ratio | 0.17 | |||||
| Days Inventory | 30.11 | |||||
| Days Sales Outstanding | 76.1 | |||||
| Days Payable | 43.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.21 | |||||
| Dividend Payout Ratio | 0.11 | |||||
| Forward Dividend Yield % | 0.21 | |||||
| 5-Year Yield-on-Cost % | 0.21 | |||||
| Shareholder Yield % | 6.55 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 3.08 | |||||
| Operating Margin % | 1.21 | |||||
| Net Margin % | 1.19 | |||||
| FCF Margin % | 2.87 | |||||
| ROE % | 5.67 | |||||
| ROA % | 3.11 | |||||
| ROIC % | 3.92 | |||||
| 3-Year ROIIC % | -17.4 | |||||
| ROC (Joel Greenblatt) % | 7.88 | |||||
| ROCE % | 7.96 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 41.43 | |||||
| PE Ratio without NRI | 51.5 | |||||
| Shiller PE Ratio | 23.41 | |||||
| Price-to-Owner-Earnings | 13.19 | |||||
| PEG Ratio | 3.16 | |||||
| PS Ratio | 0.49 | |||||
| PB Ratio | 2.3 | |||||
| Price-to-Tangible-Book | 2.27 | |||||
| Price-to-Free-Cash-Flow | 17.13 | |||||
| Price-to-Operating-Cash-Flow | 15.92 | |||||
| EV-to-EBIT | 28.66 | |||||
| EV-to-EBITDA | 25.45 | |||||
| EV-to-Revenue | 0.47 | |||||
| EV-to-FCF | 16.81 | |||||
| Price-to-Projected-FCF | 1.76 | |||||
| Price-to-DCF (Earnings Based) | 1.95 | |||||
| Price-to-DCF (FCF Based) | 0.65 | |||||
| Price-to-Median-PS-Value | 1.77 | |||||
| Price-to-Graham-Number | 3.2 | |||||
| Price-to-Net-Current-Asset-Value | 3.22 | |||||
| Earnings Yield (Greenblatt) % | 3.48 | |||||
| FCF Yield % | 5.92 | |||||
| Forward Rate of Return (Yacktman) % | 18.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Samrat Pharmachem Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 3,049.253 | ||
| EPS (TTM) (₹) | 11.7 | ||
| Beta | 0.57 | ||
| Volatility % | 55.9 | ||
| 14-Day RSI | 43.98 | ||
| 14-Day ATR (₹) | 30.670336 | ||
| 20-Day SMA (₹) | 496.87 | ||
| 12-1 Month Momentum % | 38.18 | ||
| 52-Week Range (₹) | 320 - 646 | ||
| Shares Outstanding (Mil) | 3.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Samrat Pharmachem Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Samrat Pharmachem Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Samrat Pharmachem Ltd Frequently Asked Questions
What is Samrat Pharmachem Ltd(BOM:530125)'s stock price today?
The current price of BOM:530125 is ₹478.00. The 52 week high of BOM:530125 is ₹646.00 and 52 week low is ₹320.00.
When is next earnings date of Samrat Pharmachem Ltd(BOM:530125)?
The next earnings date of Samrat Pharmachem Ltd(BOM:530125) is .
Does Samrat Pharmachem Ltd(BOM:530125) pay dividends? If so, how much?
The Dividend Yield %  of Samrat Pharmachem Ltd(BOM:530125) is 0.21% (As of Today), Highest Dividend Payout Ratio of Samrat Pharmachem Ltd(BOM:530125) was 0.24. The lowest was 0.02. And the median was 0.13. The  Forward Dividend Yield % of Samrat Pharmachem Ltd(BOM:530125) is 0.21%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers